Clicky

Swedish Orphan Biovitrum AB (publ)(SOBI) News

Date Title
Jul 25 TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)
Jul 25 Sobi Announces U.S. Food and Drug Administration Approves Doptelet® (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP)
Jul 16 Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum
Jul 15 The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
Jun 20 Sobi will showcase extensive research and clinical outcomes at ISTH 2025
May 28 Sobi to share new clinical data and research at EULAR 2025
Apr 15 Invitation: Sobi's Q1 report
Feb 20 EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN
Feb 20 Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN
Oct 9 Invitation: Sobi's Q3 2024 report
Jun 19 European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
Apr 26 Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Apr 25 Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Apr 4 Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Jan 5 Sobi's Chairman of the Board resigns due to health reasons
Nov 30 Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ)